GSE205035 Targeting CDK4/6 epigenetically impairs DNA damage repair to overcome the resistance to neoadjuvant chemotherapy in locally advanced rectal cancer
Contributors : Peng Deng ; Zhaoliang Yu ; Jing TanSeries Type : Expression profiling by high throughput sequencing ; Genome binding/occupancy profiling by high throughput sequencingOrganism : Homo sapiensResistance to neoadjuvant chemotherapy is associated tumor recurrence of locally advanced rectal cancer (LARC), which remains an unmet demand to exploit potential therapeutic strategies to improve clinical outcomes. Here we demonstrated that aberrant activation of cell cycle pathways is correlated with resistance to neoadjuvant chemotherapy in LARC. A combinatorial drug screening of 130 kinase inhibitors targeting cell ...
Source: GEO: Gene Expression Omnibus - February 26, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Genome binding/occupancy profiling by high throughput sequencing Homo sapiens Source Type: research
NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN)
Conclusion: CIPN is a common and understudied toxicity, despite being a limiting factor in the quality of life of many patients. As described in acute CIPN, our study demonstrates the relationship between chronic neuropathy and being a carrier of specific polymorphisms (C1236T and C3435T) of the ABCB1 gene in patients treated with P. In addition, there are modifiable factors (obesity, smoking, or alcohol) that may influence its development. Further prospective studies are needed to investigate genetic and clinical modifiable factors predisposing to CIPPN to develop prevention and treatment strategies. (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - February 26, 2024 Category: Drugs & Pharmacology Source Type: research
Cancers, Vol. 16, Pages 946: Self-Completion Questionnaire on Sleep Evaluation in Patients Undergoing Oxaliplatin Therapy: An Observational Study
This study aims to understand the effects of sleep complaints on health and quality of life in cancer patients treated with oxaliplatin. A study has been conducted through the creation and distribution of questionnaires to patients to investigate their complaints about sleep quality. We observed significant differences between males and females in evaluating sleep hygiene scores, the Pittsburgh Sleep Quality Index, and previous difficulty sleeping. Moreover, in females, stress, worries, and anxiety seem to play a negative role in the sleep hygiene score. The obtained results could improve the interest of healthcare personn...
Source: Cancers - February 26, 2024 Category: Cancer & Oncology Authors: Maria Valentina Mussa Sarah Allegra Tiziana Armando Silvana Storto Beatrice Ghezzo Giulia Soave Giuliana Abbadessa Francesco Chiara Massimo Di Maio Fiammetta Maria Dagnoni Silvia De Francia Tags: Article Source Type: research
Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study protocol for a multicenter, randomized phase 2 trial (T-CORE2201)
This study will enroll patients treated with GEM/nabPTX as the first-line chemotherapy for stage IV pancreatic adenocarcinoma.DISCUSSION: GEM/nabPTX is a standard first-line chemotherapy regimen for patients with advanced pancreatic cancer. Recently, the superiority of 5-fluorouracil, liposomal irinotecan, and oxaliplatin combination therapy (NALIRIFOX) to GEM/nabPTX as first-line therapy for pancreatic cancer has been reported. However, the efficacy of NALIRIFOX is inadequate. Based on previous retrospective studies, it is hypothesized that treatment efficacy will improve when levofloxacin is added to GEM/nabPTX therapy. ...
Source: Cancer Control - February 24, 2024 Category: Cancer & Oncology Authors: Hiroo Imai Yasuhiro Sakamoto Shin Takahashi Hiroyuki Shibata Atsushi Sato Kazunori Otsuka Kenji Amagai Masanobu Takahashi Takuhiro Yamaguchi Chikashi Ishioka Source Type: research
Efficacy and safety of camrelizumab combined with oxaliplatin and S-1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single-arm study
CONCLUSION: The neoadjuvant therapy with camrelizumab in combination with oxaliplatin and S-1 showed a modest pCR rate, and favorable MPR rate and safety profile in patients with gastric or gastroesophageal junction cancer.PMID:38400680 | DOI:10.1002/cam4.7006 (Source: Cancer Control)
Source: Cancer Control - February 24, 2024 Category: Cancer & Oncology Authors: Wen-Jin Zhong Jian-An Lin Chu-Ying Wu Jiantian Wang Jun-Xing Chen Huida Zheng Kai Ye Source Type: research
The potential therapeutic effect of melatonin in oxaliplatin combination therapy against chemoresistant colorectal cancer cells
CONCLUSIONS: The results of cytotoxicity assays, MTT, and flow cytometry revealed that the combination of melatonin and oxaliplatin exerts synergistic effects on induction of oxaliplatin's cytotoxicity in CRC. Our research suggests that combining the treatments of melatonin and oxaliplatin may be considered as a new approach to overcoming oxaliplatin resistance in CRC patients.PMID:38401018 | DOI:10.1007/s11033-024-09316-9 (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - February 24, 2024 Category: Molecular Biology Authors: Masoumeh Dehghanzad Mohammad Mohammadi Mohaddeseh Nejati Farhad Pouremamali Nazila Fathi Maroufi Maryam Akbarzadeh Naser Samadi Mohammad Nouri Source Type: research
The potential therapeutic effect of melatonin in oxaliplatin combination therapy against chemoresistant colorectal cancer cells
CONCLUSIONS: The results of cytotoxicity assays, MTT, and flow cytometry revealed that the combination of melatonin and oxaliplatin exerts synergistic effects on induction of oxaliplatin's cytotoxicity in CRC. Our research suggests that combining the treatments of melatonin and oxaliplatin may be considered as a new approach to overcoming oxaliplatin resistance in CRC patients.PMID:38401018 | DOI:10.1007/s11033-024-09316-9 (Source: Mol Biol Cell)
Source: Mol Biol Cell - February 24, 2024 Category: Molecular Biology Authors: Masoumeh Dehghanzad Mohammad Mohammadi Mohaddeseh Nejati Farhad Pouremamali Nazila Fathi Maroufi Maryam Akbarzadeh Naser Samadi Mohammad Nouri Source Type: research
Efficacy and safety of camrelizumab combined with oxaliplatin and S ‐1 as neoadjuvant treatment in locally advanced gastric or gastroesophageal junction cancer: A phase II, single‐arm study
ConclusionThe neoadjuvant therapy with camrelizumab in combination with oxaliplatin and S-1 showed a modest pCR rate, and favorable MPR rate and safety profile in patients with gastric or gastroesophageal junction cancer. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Wen ‐Jin Zhong,
Jian‐An Lin,
Chu‐Ying Wu,
Jiantian Wang,
Jun‐Xing Chen,
Huida Zheng,
Kai Ye Tags: RESEARCH ARTICLE Source Type: research
Prediction for oxaliplatin ‐induced liver injury using patient‐derived liver organoids
ConclusionsThese results suggested that L-OHP-induced liver injury may be caused by mitochondrial oxidative damage. Furthermore, patient-derived liver organoids may be used to assess susceptibility to L-OHP-induced liver injury in individual patients. (Source: Cancer Medicine)
Source: Cancer Medicine - February 24, 2024 Category: Cancer & Oncology Authors: Kumiko Tatsumi,
Hiroshi Wada,
Shinichiro Hasegawa,
Kei Asukai,
Shigenori Nagata,
Tomoya Ekawa,
Takashi Akazawa,
Yu Mizote,
Shintaro Okumura,
Ryosuke Okamura,
Masayuki Ohue,
Kazutaka Obama,
Hideaki Tahara Tags: RESEARCH ARTICLE Source Type: research
An Italian real-world multicenter study of patients with advanced mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) of the gastro-entero-pancreatic system treated with chemotherapy
ConclusionThis study confirms that GEP-MiNENs represent a complex disease and that over the past years the clinical management has been predominantly guided by the subjective judgment of the clinicians. Although, in this series, the NEC component appeared mostly responsible for the systemic spread and prognosis on the whole neoplasm, the lack of strong prognostic and predictive factors universally recognized seems to condition their management so far. Future prospective clinical and biomolecular studies could help clinicians to improve clinical management of GEP-MiNENs. (Source: Journal of Endocrinological Investigation)
Source: Journal of Endocrinological Investigation - February 24, 2024 Category: Endocrinology Source Type: research
Deciphering drug resistance in gastric cancer: Potential mechanisms and future perspectives
This article primarily explores the potential mechanisms of chemotherapy resistance in GC patients from five perspectives: cell death, tumor microenvironment, non-coding RNA, epigenetics, and epithelial-mesenchymal transition. Additionally, it proposes feasibility strategies to overcome drug resistance from four angles: cancer stem cells, tumor microenvironment, natural products, and combined therapy. The hope is that this article will provide guidance for researchers in the field and bring hope to more GC patients.PMID:38394851 | DOI:10.1016/j.biopha.2024.116310 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - February 23, 2024 Category: Drugs & Pharmacology Authors: Jiahua Liu Qihang Yuan Hui Guo Hewen Guan Zhijun Hong Dong Shang Source Type: research
More than shots in the dark: improving patient stratification to move closer to personalised therapies in intrahepatic cholangiocarcinoma
Cholangiocarcinomas, the second most frequent hepatic tumour after hepatocellular carcinoma, make up around 2% of all gastrointestinal malignancies. It is believed that these tumours have been occurring more frequently recently, at least in Western countries, and that this is mostly due to an increase in intrahepatic cholangiocarcinoma (iCCA).1 The combination of cisplatin and gemcitabine was established as the first-line therapy for patients with advanced cholangiocarcinoma for several years based on the findings of the ABC-02 trial. Recently, the phase III TOPAZ-1 and KEYNOTE-966 studies found a survival benefit with dur...
Source: Gut - February 23, 2024 Category: Gastroenterology Authors: Arechederra, M., Casadei Gardini, A., Raggi, C. Tags: Gut Commentary Source Type: research
GDF15 induces chemoresistance to oxaliplatin by forming a reciprocal feedback loop with Nrf2 to maintain redox homeostasis in colorectal cancer
ConclusionThis study identified a novel GDF15-Nrf2 positive feedback loop that drives L-OHP resistance and suggested that the GDF15-Nrf2 axis is a potential therapeutic target for the treatment of L-OHP-resistant CRC.Graphical Abstract (Source: Cellular Oncology)
Source: Cellular Oncology - February 22, 2024 Category: Cancer & Oncology Source Type: research
A Polymeric Nanoparticle to Co-Deliver Mitochondria-Targeting Peptides and Pt(IV) Prodrug: Toward High Loading Efficiency and Combination Efficacy
Angew Chem Int Ed Engl. 2024 Feb 21:e202402291. doi: 10.1002/anie.202402291. Online ahead of print.ABSTRACTDeveloping combination chemotherapy systems with high drug loading efficiency at predetermined drug ratios to achieve a synergistic effect is important for cancer therapy. Herein, a polymeric dual-drug nanoparticle composed of a Pt(IV) prodrug derived from oxaliplatin and a mitochondria-targeting cytotoxic peptide is constructed through emulsion interfacial polymerization, which processes high drug loading efficiency and high biocompatibility. The depolymerization of polymeric dual-drug nanoparticle and the activation...
Source: Angewandte Chemie - February 21, 2024 Category: Chemistry Authors: Jinpeng Yang Zhenlin Yang Hua Wang Yincheng Chang Jiang-Fei Xu Xi Zhang Source Type: research
